Effective April 1, 2018:
*Starting dosage is based on current dose of basal insulin.
†15 Units is the recommended starting dose for patients uncontrolled on lixisenatide, a GLP-1 RA.
‡One Unit of SOLIQUA 100/33 contains 1 Unit of Lantus® and 0.33 mcg of lixisenatide.
Titrate by 2-4 units every week until target fasting plasma glucose (FPG) is reached.
SOLIQUA 100/33 is to be dosed based on the patient's metabolic needs, blood glucose monitoring results, and glycemic goals.